Acrivon Therapeutics
Acrivon Therapeutics is a clinical‑stage oncology company leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted therapies. The company focuses on precision medicine, creating companion diagnostics and drug candidates such as ACR‑368 (prexasertib), ACR‑2316, and ACR‑7280, aiming to improve patient outcomes across diverse tumor alterations.
Acrivon Therapeutics is listed with 1 API on the APIs.io network. Tagged areas include Company, Oncology, Biotechnology, Precision Medicine, and Therapeutics.
Kin Score
APIs 1
Individual APIs this provider publishes, each with its own machine-readable definition.
Acrivon API
Acrivon Therapeutics does not expose a public API; no machine‑readable specification was found on its website or developer portal.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Commercial 2
Pricing, plans, and the legal terms of use
Company 1
The organization behind the API
Other 2
Properties that don't map to a standard resource type
Source (apis.yml)
Acrivon Therapeutics API — frequently asked questions
Does Acrivon Therapeutics have an API?
Yes. APIs.io lists 1 API from Acrivon Therapeutics, including Acrivon API.
Is the Acrivon Therapeutics API ready for AI agents?
Acrivon Therapeutics has a Kin Score of 9.4 out of 100 (minimal) and an Agent Readiness score of 3.1 (human-only), scored by API Evangelist on 2026-10-31.
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.